David F. Novack - 24 Mar 2025 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Signature
/s/ David Novack
Issuer symbol
DVAX
Transactions as of
24 Mar 2025
Net transactions value
-$71,950
Form type
4
Filing time
26 Mar 2025, 17:04:10 UTC
Previous filing
20 Mar 2025
Next filing
29 Dec 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Options Exercise $68,050 +10,000 +124% $6.80 18,078 24 Mar 2025 Direct F1
transaction DVAX Common Stock Sale $140,000 -10,000 -55% $14.00 8,078 24 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Stock Option (Right to Buy) Options Exercise -10,000 -5.1% 186,528 24 Mar 2025 Common Stock 10,000 $6.80 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024.
F2 This transaction was executed in two trades at $14.00. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F3 This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of December 16, 2019, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
F4 Not applicable.